Predicted protein targets (top 16)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PNP | P00491 | 5/20 | 0.65 |
| ▸ | ADRB1 | P08588 | 1/20 | 0.46 |
| ▸ | DNMT1 | P26358 | 1/20 | 0.46 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.46 |
| ▸ | MAPT | P10636 | 1/20 | 0.46 |
| ▸ | POLB | P06746 | 1/20 | 0.45 |
| ▸ | LMNA | P02545 | 2/20 | 0.43 |
| ▸ | SMN1; SMN2 | Q16637 | 2/20 | 0.43 |
| ▸ | TK1 | P04183 | 1/20 | 0.43 |
| ▸ | MEN1 | O00255 | 1/20 | 0.43 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.43 |
| ▸ | TP53 | P04637 | 1/20 | 0.42 |
| ▸ | HTT | P42858 | 1/20 | 0.42 |
| ▸ | PDE4D | Q08499 | 1/20 | 0.42 |
| ▸ | PDE3A | Q14432 | 1/20 | 0.42 |
| ▸ | RXFP1 | Q9HBX9 | 1/20 | 0.42 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL655857 | 1.00 | PNP (0.65) | PNPADRB1DNMT1CYP3A4MAPT | |
| SCHEMBL114652 | 0.90 | PNP (0.55) | PNPADRB1DNMT1CYP3A4MAPT | |
| SCHEMBL21779018 | 0.90 | PNP (0.55) | PNPADRB1DNMT1CYP3A4MAPT | |
| SCHEMBL195548 | 0.90 | PNP (0.55) | PNPADRB1DNMT1CYP3A4MAPT | |
| SCHEMBL13351290 | 0.89 | PNP (0.54) | PNPADRB1DNMT1CYP3A4MAPT | |
| SCHEMBL13318964 | 0.89 | PNP (0.54) | PNPADRB1DNMT1CYP3A4MAPT | |
| SCHEMBL18723297 | 0.89 | PNP (0.54) | PNPADRB1DNMT1CYP3A4MAPT | |
| SCHEMBL18952860 | 0.89 | PNP (0.54) | PNPADRB1DNMT1CYP3A4MAPT | |
| SCHEMBL3868526 | 0.89 | PNP (0.54) | PNPADRB1DNMT1CYP3A4MAPT | |
| SCHEMBL14543297 | 0.89 | PNP (0.54) | PNPADRB1DNMT1CYP3A4MAPT |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 59 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-12584168-B2 | Sample preparation method | OXFORD NANOPORE TECHNOLOGIES PLC (GB) | 2026-03-24 | — | — | US | disclosed |
| US-20260066042-A1 | METHODS AND SYSTEMS FOR HIGH-THROUGHPUT MOLECULAR ANALYSIS | OPENTRONS LABWORKS INC (US) | 2026-03-05 | — | — | US | disclosed |
| US-20250313889-A1 | SAMPLE PREPARATION METHOD | OXFORD NANOPORE TECHNOLOGIES PLC (GB) | 2025-10-09 | — | — | US | disclosed |
| US-20240182906-A1 | GENOME EDITING USING EFFECTOR OLIGONUCLEOTIDES FOR THERAPEUTIC TREATMENT | Research Foundation to Cure AIDS, Inc. (US) | 2024-06-06 | — | — | US | disclosed |
| US-20240117337-A1 | METHODS AND POLYNUCLEOTIDES FOR AMPLIFYING A TARGET POLYNUCLEOTIDE | OXFORD NANOPORE TECHNOLOGIES PLC (GB) | 2024-04-11 | — | — | US | disclosed |
| US-20240076719-A9 | METHOD | OXFORD NANOPORE TECHNOLOGIES PLC (GB) | 2024-03-07 | — | — | US | disclosed |
| US-20230295694-A1 | METHOD | OXFORD NANOPORE TECHNOLOGIES PLC (GB) | 2023-09-21 | — | — | US | disclosed |
| US-11725205-B2 | Methods and polynucleotides for amplifying a target polynucleotide | OXFORD NANOPORE TECHNOLOGIES PLC (GB) | 2023-08-15 | — | — | US | disclosed |
| US-20230250474-A1 | SAMPLE PREPARATION METHOD | OXFORD NANOPORE TECHNOLOGIES PLC (GB) | 2023-08-10 | — | — | US | disclosed |
| WO-2023147565-A2 | METHODS AND SYSTEMS FOR HIGH-THROUGHPUT MOLECULAR ANALYSIS | Opentrons LabWorks Inc. (US) | 2023-08-03 | — | — | WO | disclosed |
| EP-2242761-A1 | METHOD OF MYCOTOXIN DETECTION | Neoventures Biotechnology Inc. (CA) | 2010-10-27 | — | — | EP | disclosed |
| WO-2009086621-A1 | METHOD OF MYCOTOXIN DETECTION | NEOVENTURES BIOTECHNOLOGY INC. (CA) | 2009-07-16 | — | — | WO | disclosed |
| US-20060008813-A1 | Compositions and methods of synthesis and use of novel nucleic acid structures | ERITJA RAMON | 2006-01-12 | — | — | US | disclosed |
| EP-1228243-A4 | COMPOSITIONS AND METHODS OF SYNTHESIS AND USE OF NOVEL NUCLEIC ACID STRUCTURES | CYGENE INC (US) | 2005-07-20 | — | — | EP | disclosed |
| US-20050014164-A1 | Triplex-forming oligonucleotides containing modified purines and their applications | ERITJA RAMON (ES) | 2005-01-20 | — | — | US | disclosed |
| US-6831072-B2 | Such as 8-amino-2'deoxyadenosine by treating 8-azido-2'deoxyadenosine with aqueous solution of methylamine or dimethylamine; for targeting nucleic acids without amplification and less use of enzymes | CYGENE, INC. | 2004-12-14 | — | — | US | disclosed |
| WO-2004037981-A2 | TRIPLEX-FORMING OLIGONUCLEOTIDES CONTAINING MODIFIED PURINES AND THEIR APPLICATIONS | CYGENE LABORATORIES, INC. (US) | 2004-05-06 | — | — | WO | disclosed |
| US-20030135040-A1 | Compositions and methods of synthesis and use of novel nucleic acid structures | CYGENE, INC. | 2003-07-17 | — | — | US | disclosed |
| EP-1228243-A1 | COMPOSITIONS AND METHODS OF SYNTHESIS AND USE OF NOVEL NUCLEIC ACID STRUCTURES | Cygene, Inc. (US) | 2002-08-07 | — | — | EP | disclosed |
| WO-2001032924-A1 | COMPOSITIONS AND METHODS OF SYNTHESIS AND USE OF NOVEL NUCLEIC ACID STRUCTURES | CYGENE, INC. (US) | 2001-05-10 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-12584168-B2 | Sample preparation method | POLN, POLRMT, POLM | PNP 8/4885ADRB1 4500/4885DNMT1 274/4885 |
| US-20260066042-A1 | METHODS AND SYSTEMS FOR HIGH-THROUGHPUT MOLECULAR ANALYSIS | POLRMT, POLL, SARS1 | PNP 487/4885ADRB1 2217/4885DNMT1 1090/4885 |
| US-20030135040-A1 | Compositions and methods of synthesis and use of novel nucleic acid structures | ADAR, NSUN2, RNGTT | PNP 63/4885ADRB1 4785/4885DNMT1 36/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.